)
Visual
test
Inhibrx Biosciences
Inhibrx Biosciences (INBX) investor relations material
Inhibrx Biosciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Completed sale of INBRX-101 and spin-off, now focused on two clinical programs: ozekibart and INBRX-106.
Pipeline includes ongoing trials in chondrosarcoma, colorectal cancer, and head and neck squamous cell carcinoma.
Financial highlights
Cash and cash equivalents were $124.2 million as of December 31, 2025.
Net loss for Q4 2025 was $32.8 million ($2.11/share), improved from $47.9 million ($3.09/share) in Q4 2024.
Net loss for FY 2025 was $140.1 million ($9.04/share), compared to net income of $1.7 billion ($114.01/share) in FY 2024, which included a one-time gain from the INBRX-101 transaction.
Research and development expenses decreased to $25.3 million in Q4 2025 (from $33.4 million in Q4 2024) and to $113.0 million in FY 2025 (from $203.7 million in FY 2024).
General and administrative expenses dropped to $5.6 million in Q4 2025 (from $16.7 million in Q4 2024) and to $23.3 million in FY 2025 (from $127.9 million in FY 2024).
Other expense was $1.9 million in Q4 2025 versus other income of $2.1 million in Q4 2024; FY 2025 other expense was $5.0 million versus FY 2024 other income of $2.0 billion (driven by the INBRX-101 gain).
Outlook and guidance
Plans to submit BLA for ozekibart in unresectable/metastatic chondrosarcoma to FDA in early Q2 2026.
Progression-free survival data for ozekibart in colorectal cancer expected in Q2 2026; FDA meeting for accelerated approval in Ewing Sarcoma and fourth-line colorectal cancer planned for H2 2026.
Interim ORR data for INBRX-106 in HNSCC with pembrolizumab expected in Q2 2026; PFS data at ESMO 2026 Congress in Q4 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Inhibrx Biosciences
- INBRX-106 and ozekibart show strong clinical promise, targeting major oncology markets.INBX
Investor presentation20 Mar 2026 - Spin-off and asset sale drove $1.7B net income; strong cash, clinical data expected in 12 months.INBXQ4 202412 Dec 2025
- Net loss of $107.2M, $1.3M revenue, $153.1M cash, and strong clinical progress for ozekibart.INBXQ3 202524 Nov 2025
- Ozekibart doubled PFS in chondrosarcoma and showed high response rates in CRC and Ewing sarcoma.INBXStudy Result27 Oct 2025
- Q2 2025 net loss was $28.7M, revenue $1.3M, and cash reserves $186.6M.INBXQ2 202514 Oct 2025
Next Inhibrx Biosciences earnings date
Q1 202615 May, 2026
Inhibrx Biosciences
Next Inhibrx Biosciences earnings date
Q1 202615 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage